20 results
424B3
APYP
Appyea, Inc
26 Feb 24
Prospectus supplement
11:13am
to demonstrate to the satisfaction of the FDA that a product candidate is safe and effective for any indication;
the FDA may not accept the clinical … and effective in Clinical Trials to the FDA’s satisfaction;
physicians may not receive any reimbursement from third-party payers, or the level
POS AM
APYP
Appyea, Inc
14 Feb 24
Prospectus update (post-effective amendment)
9:29am
as applicable may disagree with the design or implementation of our clinical trials;
we may be unable to demonstrate to the satisfaction of the FDA … satisfaction;
physicians may not receive any reimbursement from third-party payers, or the level of reimbursement may be insufficient to support widespread
POS AM
EX-5.1
APYP
Appyea, Inc
14 Feb 24
Prospectus update (post-effective amendment)
9:29am
examined and relied upon the originals or copies certified or otherwise identified to our satisfaction of (i) the Company’s articles of incorporation
POS AM
APYP
Appyea, Inc
8 Feb 24
Prospectus update (post-effective amendment)
3:13pm
as applicable may disagree with the design or implementation of our clinical trials;
we may be unable to demonstrate to the satisfaction of the FDA … satisfaction;
physicians may not receive any reimbursement from third-party payers, or the level of reimbursement may be insufficient to support widespread
424B3
kn1al89zpfd4
21 Nov 22
Prospectus supplement
1:17pm
8-K
EX-10.2
d9il2a7gf8qsg0gulwt
13 Feb 20
Departure of Directors or Certain Officers
5:17pm
PRE 14A
7hey75kw9mpeuxf
20 Sep 19
Preliminary proxy
2:46pm
8-K
EX-10.2
fycvtk2
12 Jul 18
Entry into a Material Definitive Agreement
12:29pm
8-K
EX-10.1
rqff4u9e11dp6yq
12 Jul 18
Entry into a Material Definitive Agreement
12:29pm
8-K
EX-10.3
5n7hvv bi84wcqasn6i
12 Jul 18
Entry into a Material Definitive Agreement
12:29pm
- Prev
- 1
- Next